Frontiers in Probing Alzheimer’s Disease Biomarkers with Fluorescent Small Molecules
Author(s) -
Yong Woong Jun,
Seo Won Cho,
Junyang Jung,
Youngbuhm Huh,
Young Soo Kim,
Dokyoung Kim,
Kyo Han Ahn
Publication year - 2019
Publication title -
acs central science
Language(s) - English
Resource type - Journals
eISSN - 2374-7951
pISSN - 2374-7943
DOI - 10.1021/acscentsci.8b00951
Subject(s) - dementia , in vivo , fluorescence , alzheimer's disease , molecular imaging , amyloid β , amyloid (mycology) , ex vivo , disease , biomarker , neuroscience , preclinical imaging , chemistry , medicine , nanotechnology , pathology , biology , biochemistry , materials science , physics , microbiology and biotechnology , quantum mechanics
Alzheimer's disease (AD) is the most common form of dementia. The pathogenesis of the disease is associated with aggregated amyloid-β, hyperphosphorylated tau, a high level of metal ions, abnormal enzyme activities, and reactive astrocytes. This outlook gives an overview of fluorescent small molecules targeting AD biomarkers for ex vivo and in vivo imaging. These chemical imaging probes are categorized based on the potential biomarkers, and their pros and cons are discussed. Guidelines for designing new sensing strategies as well as the desirable properties to be pursued for AD fluorescence imaging are also provided.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom